Kevin L. He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin L. He has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Guillaume Francois Chanfreau
University of California, Los Angeles
40 shared publications - Carla M. Koehler
UCLA 2 Department of Chemistry and Biochemistry Los Angeles, CA 90095
34 shared publications - Matthew R. Krieger
Department of Chemistry and Biochemistry at UCLA, Los Angeles, USA
34 shared publications - Michael A. Teitell
Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA.
34 shared publications - Angela L. Zhang
University of California, Los Angeles 4 Department of Integrative Biology and Physiology Los Angeles, California
33 shared publications - David B. Shackelford
Pulmonary and Critical Care Medicine, David Geffen School of Medicine (DGSOM), University of California Los Angeles (UCLA), Los Angeles, USA
33 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Read counts mapped to mitochondrial genome
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Read counts mapped to mitochondrial genome
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
RIP-seq Histogram of H1944, H23 and PC9 with and without IMT-1 Treatment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
RIP-seq Histogram of H1944, H23 and PC9 with and without IMT-1 Treatment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Representative peak analysis for heteroplasmy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Representative peak analysis for heteroplasmy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
IF of cell lines with IMT-1 Treatment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
IF of cell lines with IMT-1 Treatment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Enrichment of mtdsRNAs is captured through dsRNA-seq in selected NSCLC cell lines. A, Workflow of RIP-seq. B, Quantification of unique reads detected by RIP-seq. Reads from the heavy (red) and light (blue) strands were mapped to the mitochondrial genome ChrMT. See Supplementary Fig. S1 for an enlarged view of the sequencing data. C and D, Statistical analysis of successfully aligned reads per genomic feature (gene, CDS, rRNA, exon, and D-loop, with either tRNA included or excluded). Bar represents average. Error bars represent ± SEM. P values are represented as is. One-way ANOVA was completed. Each dot represents an independent experiment (n = 3). E, Mitochondrial genome mapped with primers used for long-read sequencing. Primers can be found in Supplementary Table S1. Green: ND5 Fwd → RNR2 Rev. Blue: RNR2 Fwd → Cox3 Rev. Orange: Cox3 Fwd → ND5 Rev. F, Gel showing the bands generated by PCR across three different cell lines used for ADAR sequencing. Representative of three independent experiments (n = 3).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Enrichment of mtdsRNAs is captured through dsRNA-seq in selected NSCLC cell lines. A, Workflow of RIP-seq. B, Quantification of unique reads detected by RIP-seq. Reads from the heavy (red) and light (blue) strands were mapped to the mitochondrial genome ChrMT. See Supplementary Fig. S1 for an enlarged view of the sequencing data. C and D, Statistical analysis of successfully aligned reads per genomic feature (gene, CDS, rRNA, exon, and D-loop, with either tRNA included or excluded). Bar represents average. Error bars represent ± SEM. P values are represented as is. One-way ANOVA was completed. Each dot represents an independent experiment (n = 3). E, Mitochondrial genome mapped with primers used for long-read sequencing. Primers can be found in Supplementary Table S1. Green: ND5 Fwd → RNR2 Rev. Blue: RNR2 Fwd → Cox3 Rev. Orange: Cox3 Fwd → ND5 Rev. F, Gel showing the bands generated by PCR across three different cell lines used for ADAR sequencing. Representative of three independent experiments (n = 3).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
IF of cell lines with IMT-1 Treatment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
IF of cell lines with IMT-1 Treatment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Enrichment of mtdsRNAs is captured through dsRNA-seq in selected NSCLC cell lines. A, Workflow of RIP-seq. B, Quantification of unique reads detected by RIP-seq. Reads from the heavy (red) and light (blue) strands were mapped to the mitochondrial genome ChrMT. See Supplementary Fig. S1 for an enlarged view of the sequencing data. C and D, Statistical analysis of successfully aligned reads per genomic feature (gene, CDS, rRNA, exon, and D-loop, with either tRNA included or excluded). Bar represents average. Error bars represent ± SEM. P values are represented as is. One-way ANOVA was completed. Each dot represents an independent experiment (n = 3). E, Mitochondrial genome mapped with primers used for long-read sequencing. Primers can be found in Supplementary Table S1. Green: ND5 Fwd → RNR2 Rev. Blue: RNR2 Fwd → Cox3 Rev. Orange: Cox3 Fwd → ND5 Rev. F, Gel showing the bands generated by PCR across three different cell lines used for ADAR sequencing. Representative of three independent experiments (n = 3).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
Enrichment of mtdsRNAs is captured through dsRNA-seq in selected NSCLC cell lines. A, Workflow of RIP-seq. B, Quantification of unique reads detected by RIP-seq. Reads from the heavy (red) and light (blue) strands were mapped to the mitochondrial genome ChrMT. See Supplementary Fig. S1 for an enlarged view of the sequencing data. C and D, Statistical analysis of successfully aligned reads per genomic feature (gene, CDS, rRNA, exon, and D-loop, with either tRNA included or excluded). Bar represents average. Error bars represent ± SEM. P values are represented as is. One-way ANOVA was completed. Each dot represents an independent experiment (n = 3). E, Mitochondrial genome mapped with primers used for long-read sequencing. Primers can be found in Supplementary Table S1. Green: ND5 Fwd → RNR2 Rev. Blue: RNR2 Fwd → Cox3 Rev. Orange: Cox3 Fwd → ND5 Rev. F, Gel showing the bands generated by PCR across three different cell lines used for ADAR sequencing. Representative of three independent experiments (n = 3).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
MtdsRNA is identified beyond NSCLC cell lines. A, Summary table of the results. B and C, Fraction of reads mapped to light (red) and heavy (blue) strands of mitochondrial genome (ChrMT) detected in LUAD and LUSC patient samples. Each bar represents one patient. D and E, Fraction of reads uniquely mapped to light (red) and heavy (blue) strands of mitochondrial genome (ChrMT) in COAD and breast cancer (BRCA) patient samples. Each bar represents one patient. F, Fraction of reads mapped to light (red) and heavy (blue) strands of mitochondrial genome (ChrMT) detected in prostate cancer cell lines and patient samples. G, Box plot of fraction of reads mapped to the light strand of chrMT in prostate cancer cell lines and patient samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Characterization of Mitochondrial Double-Stranded RNA Levels in Non–Small Cell Lung Carcinoma
MtdsRNA is identified beyond NSCLC cell lines. A, Summary table of the results. B and C, Fraction of reads mapped to light (red) and heavy (blue) strands of mitochondrial genome (ChrMT) detected in LUAD and LUSC patient samples. Each bar represents one patient. D and E, Fraction of reads uniquely mapped to light (red) and heavy (blue) strands of mitochondrial genome (ChrMT) in COAD and breast cancer (BRCA) patient samples. Each bar represents one patient. F, Fraction of reads mapped to light (red) and heavy (blue) strands of mitochondrial genome (ChrMT) detected in prostate cancer cell lines and patient samples. G, Box plot of fraction of reads mapped to the light strand of chrMT in prostate cancer cell lines and patient samples.